Loading...
Antibodies targeting the epidermal growth factor receptor (EGFr) have single-agent activity in advanced colorectal cancer (CRC) and improve outcomes when combined with chemotherapy. The benefit of EGFr-targeted therapy in CRC is limited to patients with KRAS wild-type status, and two EGFr-targeted agents — panitumumab and cetuximab — have been approved to treat metastatic CRC.
Investigators now report the results of the first randomized phase III comparison of these agents in patients with chemotherapy-refractory, metastatic KRAS wild-type disease. The industry-sponsored, international, open-label, noninferiority trial involved 999 patients who received intravenous panitumumab (6 mg/kg once every 2 weeks) or intravenous cetuximab (400 mg/m2 …